Rheumatoid Arthritis Diagnosis Tests Market to Cross US$ 1,002.0 Mn by 2027

Global Market Study
on Rheumatoid
Arthritis Diagnosis
Tests: Rheumatoid Factor (RF) Serology Tests Segment to
Significantly Contribute to Global Market Growth in the Coming
Persistence Market Research has come up with revised forecasts on the global
rheumatoid arthritis diagnosis test market. According to this latest market report
titled ‘Rheumatoid Arthritis Diagnosis Test Market: Global Industry Analysis
(2012-2016) and Forecast (2017-2027)’, the global market is expected to
expand at a CAGR of 6.3% during the forecast period 2017–2027. The global
market is estimated to reach a valuation of more than US$ 1 Bn by the end of
the year of assessment from a value of about US$ 545 Mn in 2017.
The market is segmented based on test type, end user and region. On the basis
of test type, the market has been segmented into two segments such as serology
tests and monitoring RA treatment efficiency tests. The serology tests segment
is further divided into six sub-segments are-erythrocyte sedimentation rate
(ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP),
antinuclear antibody (ANA), uric acid and other tests. The monitoring RA
treatment efficiency tests segment is also further divided into salicylate level
count, muscle enzyme tests (CPK, Aldolase) and creatinine test. Serology tests
segment is expected to be the fastest growing segment over the forecast period,
registering the significant CAGR of 6.5% over the forecast period. Increasing
incidence of autoimmune diseases, off-label prescription of NSAIDs and other
pain management drugs are projected to increase demand for RA diagnosis.
Commercialization of rapid diagnostic test, especially in anti-CCP test would
provide key growth opportunities for RA test kits manufacturers. However,
higher costs of these test kits and limited sensitivity when performed as
individual test are major restraining factors for this market. Revenue
contribution from serology segment, the anti-CCP test segment has been
estimated to be the highest, accounting for 31.1% of the total rheumatoid
arthritis market share in 2016 and is expected to be one of the most lucrative
segments over the forecast period. Limited sensitivity of other tests such as
ANA antibody and RF test provide competitive advantage over anti-CCP test.
However, availability of these tests at remote location of Asia Pacific region is
a major challenge for the market.
Browse Full Research Report:
On the basis of end user, the market has been segmented into diagnostics
laboratories, ambulatory surgical centers and hospitals. Ambulatory surgical
centers segment is projected to be the fastest-growing segment, registering a
6.6% value CAGR in terms of revenue.
On the basis of region, the rheumatoid arthritis diagnosis tests market is
segmented into North America, Latin America, Europe, Asia Pacific, and
Middle East & Africa. Europe and Asia Pacific regions have been estimated to
collectively account for around 60% revenue share in 2016, owing to higher
adoption of RA diagnosis test and increasing prevalence rate of autoimmune
diseases. However, high RA prevalent region (North America) tend to become
saturated in terms of revenue generation, owing to increasing awareness and
healthcare spending for RA treatment and monitoring.
The report begins with an overview of the rheumatoid arthritis diagnosis tests
market in terms of value, and a detailed analysis of key trends, drivers and
restraints, and opportunities, which are the main factors impelling growth of the
rheumatoid arthritis test market. Impact analysis of key growth drivers and
restraints based on the weighted average of each of these factors in a modelbased approach is included in the report. The report provides in-depth
information on potential scope of high-end confirmatory testing kits to provide
clients with crystal clear decision-making insights.
Request and Download Sample [email protected]
Key players operating in the rheumatoid arthritis diagnosis tests market include
Abbott Diagnostics (Abbott Laboratories), Antibodies Inc., Beckman Coulter,
Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens
Healthcare GmbH, and Thermo Fisher Scientific Inc., Bio Rad Laboratories
Inc. and Genway Biotech, Inc. (Aviva Systems Biology Corp.).
These companies are focusing on commercialization of cost-effective, highlysensitive and rapid test kits. However, there is stiff competition from local
manufacturers owing to low entry barriers and limited awareness about RA test
efficiency among physicians.
Download and View Report TOC, Figures and Tables
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our
research model is a unique collaboration of data analytics and market research
methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from
multi-dimensional sources. By deploying real-time data collection, big data, and
customer experience analytics, we deliver business intelligence for
organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: [email protected]
Web: http://www.persistencemarketresearch.com